Jon Arnason

Featured in: Favicon

thelancet.com Favicon

bloodjournal.org Favicon

futuremedicine.com Favicon

patientpower.info

Articles

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen | Future Oncology

Mar 28, 2024 | futuremedicine.com | Jeremy Abramson |Scott Solomon |Jon Arnason |Patrick Johnston

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThe authors of this article thank the people who participated in this study and their families, as well as the investigators, co-investigators, and clinical site staff. Financial disclosureThe TRANSFORM study was sponsored by Celgene, a Bristol-Myers Squibb Company.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →